Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorthalidone

FDA-approved product (tablet, oral), marketed as Chlorthalidone, Hemiclor, Hygroton and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Chlorthalidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Congestive heart failure
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorthalidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorthalidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

    NCT07645300 · start 2026-10-01

    Registered record
    Registry ID
    NCT07645300
    Conditions
    Hypertension Treated With Antihypertensive Drugs; Chronic Kidney Disease, 3B and 4
    Interventions
    phase 2A Chlorthalidone; phase 2A Spironolactone; phase 2A Chlorthalidone + Spironolactone; phase 2B Chlorthalidone LD + Spironolactone LD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2032-06-30
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension Treated With Antihypertensive Drugs; Chronic Kidney Disease, 3B and 4
    Interventionphase 2A Chlorthalidone; phase 2A Spironolactone; phase 2A Chlorthalidone + Spironolactone; phase 2B Chlorthalidone LD + Spironolactone LD
    PhasePhase 2
    Registry statusNot yet recruiting

  • Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

    NCT07238400 · start 2026-03-20

    Registered record
    Registry ID
    NCT07238400
    Conditions
    Hypertension
    Interventions
    Eplerenone 100 mg daily; Chlorthalidone 25 mg daily; Potassium Placebo; Potassium Chloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-20
    Completion
    2029-03-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionEplerenone 100 mg daily; Chlorthalidone 25 mg daily; Potassium Placebo; Potassium Chloride
    PhasePhase 2
    Registry statusRecruiting

  • CaOx Stone Prevention

    NCT07225764 · start 2025-10-23

    Registered record
    Registry ID
    NCT07225764
    Conditions
    Kidney Stones
    Interventions
    Chlorthalidone; Low oxalate diet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-23
    Completion
    2027-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    InterventionChlorthalidone; Low oxalate diet
    PhasePhase 4
    Registry statusRecruiting

  • Arterial Stiffness and Blood Pressure

    NCT06495710 · start 2025-05-01

    Registered record
    Registry ID
    NCT06495710
    Conditions
    Hypertension; Vascular Stiffness; Aging
    Interventions
    Blood pressure treatment algorithm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-05-01
    Completion
    2028-12-31
    Enrolment
    228

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Vascular Stiffness; Aging
    InterventionBlood pressure treatment algorithm
    PhaseNot applicable
    Registry statusRecruiting

  • Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

    NCT05593055 · start 2023-08-25

    Registered record
    Registry ID
    NCT05593055
    Conditions
    Hypertension; Left Ventricular Hypertrophy
    Interventions
    Eplerenone; Chlorthalidone; Potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-08-25
    Completion
    2027-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Left Ventricular Hypertrophy
    InterventionEplerenone; Chlorthalidone; Potassium
    PhasePhase 4
    Registry statusRecruiting

  • Skin Sodium and Salt Sensitivity of Blood Pressure

    NCT05976438 · start 2023-08

    Registered record
    Registry ID
    NCT05976438
    Conditions
    Hypertension
    Interventions
    Amlodipine; Chlortalidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-08
    Completion
    2024-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmlodipine; Chlortalidone
    PhaseNot applicable
    Registry statusUnknown

  • Diuretic Use in Hemodialysis Patients With Residual Renal Function

    NCT05915286 · start 2023-05-29

    Registered record
    Registry ID
    NCT05915286
    Conditions
    End Stage Renal Disease on Dialysis
    Interventions
    Furosemide; Chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-05-29
    Completion
    2025-02-21
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease on Dialysis
    InterventionFurosemide; Chlorthalidone
    PhasePhase 4
    Registry statusTerminated

  • A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension

    NCT07116863 · start 2022-06-21

    Registered record
    Registry ID
    NCT07116863
    Conditions
    Essential Hypertension
    Interventions
    KDF1901-R0; KDF1901-L; KDF1901; KDF1901-R1
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-06-21
    Completion
    2024-09-13
    Enrolment
    286

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionKDF1901-R0; KDF1901-L; KDF1901; KDF1901-R1
    PhasePhase 3
    Registry statusCompleted

  • Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment

    NCT05411991 · start 2022-06-12

    Registered record
    Registry ID
    NCT05411991
    Conditions
    Acute Heart Failure; Diuretics Drug Reactions
    Interventions
    UNa measurement after intravenous loop diuretic bolus; Intravenous acetazolamide 500 mg OD; Intravenous bumetanide TID; Oral chlorthalidone OD; Intravenous canrenoate 200 mg OD; Maintenance infusion; Oral potassium supplements; Intravenous hypertonic saline; Switch to oral diuretic therapy; Usual AHF care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-06-12
    Completion
    2024-07-01
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure; Diuretics Drug Reactions
    InterventionUNa measurement after intravenous loop diuretic bolus; Intravenous acetazolamide 500 mg OD; Intravenous bumetanide TID; Oral chlorthalidone OD +6 more
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

    NCT06282549 · start 2022-06-08

    Registered record
    Registry ID
    NCT06282549
    Conditions
    Essential Hypertension
    Interventions
    Telmisartan/Amlodipine/Chlorthalidone(Truset)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-06-08
    Completion
    2027-03-31
    Enrolment
    1,219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionTelmisartan/Amlodipine/Chlorthalidone(Truset)
    PhaseNot recorded
    Registry statusActive not recruiting

  • Hypertension in Young Adults Trial

    NCT05370599 · start 2022-04-15

    Registered record
    Registry ID
    NCT05370599
    Conditions
    Hypertension
    Interventions
    Anti-hypertensive agent: amlodipine; Anti-hypertensive agent: Chlorthalidone; Anti-hypertensive agent: Losartan; Home BP monitoring with cuffed device; Home BP monitoring with cuffed device + BP patch; Home BP monitoring with cuffed device + BP watch
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-04-15
    Completion
    2026-01-07
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAnti-hypertensive agent: amlodipine; Anti-hypertensive agent: Chlorthalidone; Anti-hypertensive agent: Losartan; Home BP monitoring with cuffed device +2 more
    PhasePhase 2
    Registry statusTerminated

  • Spironolactone in CKD Enabled by Chlorthalidone: PILOT

    NCT05222191 · start 2022-02-01

    Registered record
    Registry ID
    NCT05222191
    Conditions
    Renal Insufficiency; Chronic Hypertension
    Interventions
    Spironolactone; Chlorthalidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-02-01
    Completion
    2023-12-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency; Chronic Hypertension
    InterventionSpironolactone; Chlorthalidone; Placebo
    PhasePhase 2
    Registry statusUnknown

  • OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

    NCT05293756 · start 2021-02-14

    Registered record
    Registry ID
    NCT05293756
    Conditions
    Hypertension; Self-Management; Technology; Quality of Life
    Interventions
    OPTIMA-BP Intervention
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-02-14
    Completion
    2027-05-31
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Self-Management; Technology; Quality of Life
    InterventionOPTIMA-BP Intervention
    PhaseNot applicable
    Registry statusRecruiting

  • Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

    NCT04830449 · start 2020-10-29

    Registered record
    Registry ID
    NCT04830449
    Conditions
    Hypertension
    Interventions
    HCP1904-2; RLD2001-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-10-29
    Completion
    2021-08-24
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHCP1904-2; RLD2001-2
    PhasePhase 3
    Registry statusCompleted

  • A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

    NCT04470830 · start 2019-09-11

    Registered record
    Registry ID
    NCT04470830
    Conditions
    Essential Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-11
    Completion
    2023-05-25
    Enrolment
    718

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted